Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12063MR)

This product GTTS-WQ12063MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12063MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10352MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ6424MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ10105MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ6573MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ4140MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ13531MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ8373MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ15448MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW